Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $557,250.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 75,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $7.43, for a total value of $557,250.00. Following the sale, the insider now owns 618,524 shares of the company’s stock, valued at $4,595,633.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total transaction of $456,600.00.

Tango Therapeutics Trading Up 0.3 %

TNGX opened at $7.61 on Monday. Tango Therapeutics, Inc. has a 1-year low of $2.47 and a 1-year high of $13.03. The business has a 50 day moving average of $8.58 and a 200-day moving average of $9.34. The stock has a market capitalization of $812.29 million, a price-to-earnings ratio of -6.92 and a beta of 0.84.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). Tango Therapeutics had a negative net margin of 278.55% and a negative return on equity of 41.96%. The company had revenue of $5.43 million during the quarter, compared to the consensus estimate of $7.86 million. Equities analysts predict that Tango Therapeutics, Inc. will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in Tango Therapeutics by 12.3% in the 3rd quarter. FMR LLC now owns 11,645,741 shares of the company’s stock valued at $131,131,000 after acquiring an additional 1,276,945 shares in the last quarter. Boxer Capital LLC raised its stake in shares of Tango Therapeutics by 15.1% in the fourth quarter. Boxer Capital LLC now owns 8,198,642 shares of the company’s stock valued at $81,167,000 after purchasing an additional 1,075,000 shares in the last quarter. Vanguard Group Inc. lifted its position in Tango Therapeutics by 7.2% in the third quarter. Vanguard Group Inc. now owns 2,939,843 shares of the company’s stock worth $33,103,000 after purchasing an additional 197,624 shares during the period. RTW Investments LP acquired a new stake in Tango Therapeutics during the fourth quarter worth $19,471,000. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Tango Therapeutics by 47.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock valued at $19,760,000 after buying an additional 564,971 shares during the period. 78.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TNGX has been the subject of a number of recent research reports. Cantor Fitzgerald started coverage on shares of Tango Therapeutics in a report on Thursday, April 4th. They issued an “overweight” rating for the company. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Monday, March 18th. Piper Sandler began coverage on Tango Therapeutics in a research report on Monday, February 12th. They set an “overweight” rating and a $18.00 target price for the company. Finally, HC Wainwright boosted their target price on shares of Tango Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.25.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.